'Extraordinary' generics price hikes hit Medicare Part D amid big reduction overall

meds

Generic drug prices in Medicare Part D decreased significantly in recent years, a new report from the U.S. Government Accountability Office (GAO) says. So why the worry about price hikes? Hundreds of products saw “extraordinary price increases," that's why.

For a group of 2,378 generic drugs--including those that entered or exited the market from 2010 to 2015--Medicare Part D prices fell overall by 59%.

But “established generics"--the 1,441 drugs that stayed on the market the entire time--fell by just 22%. More than 300 cases of “extraordinary price increases” kept prices from falling further, the GAO said.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Those extraordinary hikes amounted to at least 100%--and in those cases, the prices rarely dropped afterward, the agency said.


'Established' drug prices fell less


The findings are in line with a recent Los Angeles Times investigation that showed some generic drugmakers followed competitors’ price increases by jacking up the stickers on their own meds. For example, ursodiol, a generic gallstone drug made by 8 companies that had cost 45 cents a capsule: In May 2014, Lannett raised the price by more than 1,000% to $5.10 each, and competitors soon followed with similar pricing.

That’s exactly the kind of maneuver Democratic presidential candidate Hillary Clinton is targeting with her new plan, unveiled earlier this month as part of a larger effort to tackle healthcare costs. She proposed a panel that would look for “excessive, outlier” price hikes. Then, enforcement actions could include fines and other measures to increase competition.

That panel would not pass muster with lawmakers, however, according to Evercore ISI policy analyst Terry Haines. Shortly after the announcement, Haines said a “‘citizen panel’ is not something that would survive a bipartisan legislative process.” Pfizer CEO Ian Read chimed in, saying that overall, the proposals are “very negative for innovation.”

Worth noting is that the GAO data end in the second quarter of 2015, and “most investors understand that generic pricing has seen a meaningful change coming into 2016,” Evercore ISI analysts pointed out.

Even still, the Generic Pharmaceutical Association is praising the newest GAO report. “At a time when everyone is looking for cost saving solutions, it is important to note that the GAO findings are consistent with the prevailing market trend--generic drug prices overall continue to decline year over year,” GPhA CEO Chip Davis said in a statement.

Related Articles:
Amid still-raging EpiPen scandal, Clinton rolls out plan to fight drug price hikes
Some generic drug prices soar despite heavy competition
Pfizer CEO calls Clinton drug plan 'very negative for innovation'
Hillary's latest drug-price tweet put the fear of government action into biopharma stocks
Hillary Clinton plan to curb drug prices puts the screws to drugmakers and insurers

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.